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Background: Anticoagulation during PCI is limited by unpredictable pharmacodynamics and lack of active reversibility. The REG1 System, a 
regulatable RNA aptamer pair composed of a FIX inhibitor RB006 and its active control agent RB007, has shown rapid onset and predictable 
anticoagulation in phase 1 studies. We conducted a study to assess REG1 during PCI.
Methods: REVERSAL PCI was a randomized trial comparing REG1 (n=20) with UFH (n=4) in elective PCI. RB006 was given as a 1 mg/kg IV bolus. 
Two reversal strategies were tested. 1) Partial reversal with a 50% reversal dose of RB007 post-PCI followed by complete reversal at 4 hours. 2) 
Complete reversal with RB007 immediately post-PCI. Anticoagulation was monitored with plasma and whole blood aPTT, and ACT.
Results: Coagulation measures at 5 min post RB006 dosing and at the end of PCI were: Plasma aPTT 2.5 fold and 2.4 fold above baseline; Whole 
Blood aPTT 148.5 and 145 sec; ACT 223 and 236 sec (see figure). In the respective assays, partial reversal RB007 resulted in 51±14% to 68±15% 
reversal of RB006, while complete reversal RB007 resulted in 93±11% to 103±13% reversal of RB006. All PCI procedures were successful, with 
minimal bleeding and no intraprocedural thrombotic events.
Conclusions: REG1 provides stable, controllable anticoagulation capable of supporting of PCI. This approach to anticoagulation may provide an 
alternative to current therapy to better address the balance of ischemia and bleeding, and merits further evaluation in larger randomized studies.
